Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.68 |
| ▸ | JAK3 | P52333 | 7/20 | 0.68 |
| ▸ | JAK1 | P23458 | 5/20 | 0.68 |
| ▸ | BTK | Q06187 | 3/20 | 0.54 |
| ▸ | EGFR | P00533 | 7/20 | 0.53 |
| ▸ | SRC | P12931 | 4/20 | 0.53 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | HCK | P08631 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | ITK | Q08881 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14630543 | 1.00 | JAK2 (0.68) | JAK2JAK3JAK1BTKEGFR | |
| SCHEMBL18599031 | 0.90 | BTK (0.55) | JAK2JAK3JAK1BTKEGFR | |
| SCHEMBL14654266 | 0.89 | BTK (0.55) | JAK2JAK3JAK1BTKEGFR | |
| SCHEMBL31693318 | 0.89 | JAK2 (0.54) | JAK2JAK3JAK1BTKEGFR | |
| SCHEMBL31693347 | 0.89 | JAK2 (0.54) | JAK2JAK3JAK1BTKEGFR | |
| SCHEMBL1497755 | 0.89 | EGFR (0.68) | JAK2JAK3JAK1BTKEGFR | |
| SCHEMBL29671261 | 0.89 | EGFR (0.68) | JAK2JAK3JAK1BTKEGFR | |
| SCHEMBL29351446 | 0.89 | EGFR (0.68) | JAK2JAK3JAK1BTKEGFR | |
| SCHEMBL1497754 | 0.89 | EGFR (0.68) | JAK2JAK3JAK1BTKEGFR | |
| SCHEMBL4823191 | 0.89 | EGFR (0.68) | JAK2JAK3JAK1BTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123156-A1 | HETEROARYL COMPOUND HAVING DRUG ACTIVITY | SHANGHAI DUDE MEDICAL TECHNOLOGY CO., LTD | 2020-04-23 | — | — | US | disclosed |
| EP-3257855-B1 | METHOD FOR PREPARING IBRUTINIB | SHANGHAI DUDE MEDICAL SCIENCE AND TECH CO LTD (CN) | 2020-04-22 | — | — | EP | disclosed |
| EP-2734529-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20180044339-A1 | PROCESS FOR PREPARING IBRUTINIB | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2018-02-15 | — | — | US | disclosed |
| EP-3257855-A1 | METHOD FOR PREPARING IBRUTINIB | Shanghai Dude Medical Science and Technology Co., Ltd. (CN) | 2017-12-20 | — | — | EP | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
| EP-2548877-A1 | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors | MSD Oss B.V. (NL) | 2013-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123156-A1 | HETEROARYL COMPOUND HAVING DRUG ACTIVITY | BTK, LYN, LCK | JAK2 40/4885JAK3 341/4885JAK1 326/4885 |
| US-20170008899-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | JAK2 8/4885JAK3 19/4885JAK1 10/4885 |
| US-20180044339-A1 | PROCESS FOR PREPARING IBRUTINIB | BTK, SYK, ABL1 | JAK2 5/4885JAK3 24/4885JAK1 19/4885 |
| US-20140221333-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | JAK2 8/4885JAK3 17/4885JAK1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.